)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Elicera Therapeutics (ELIC) investor relations material
Elicera Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary29 Aug, 2025
Executive summary
Operating loss for Q2 2025 improved to SEK -2.9M from SEK -5.8M year-over-year, with a similar trend for the half-year period, reflecting increased grants and reduced costs.
Four out of six patients in the first two CARMA study cohorts achieved complete metabolic response, with no serious adverse events reported.
ELC-100 received Orphan Drug Designation in the U.S. for pancreatic neuroendocrine tumors.
Successful warrant program and share issue raised SEK 22M, extending capitalization until mid-2027.
Financial highlights
Q2 2025 operating loss: SEK -2,892,341 (Q2 2024: -5,841,409); H1 2025: SEK -10,961,745 (H1 2024: -11,274,831).
Loss for Q2 2025: SEK -2,732,070 (Q2 2024: -5,622,779); H1 2025: SEK -10,745,532 (H1 2024: -10,992,456).
Cash flow from operating activities H1 2025: SEK -6,736,135 (H1 2024: -16,997,666).
Cash and cash equivalents at period end: SEK 39,661,563 (H1 2024: 32,864,607).
Earnings per share H1 2025: SEK -0.25 (H1 2024: -0.39).
Outlook and guidance
Capitalization is projected to last until mid-2027, supporting completion of the CARMA study.
Final reporting for the ELC-100 Phase I/IIa study is postponed to year-end 2025 due to a database transition.
Continued focus on securing funding and partnerships for preclinical programs, especially ELC-401 for glioblastoma.
ELC-301's efficacy in prior CD19 CAR T failures?
ELC-100 final report timeline after delay?
How does current funding support CARMA study?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Elicera Therapeutics earnings date
Q3 202514 Nov, 2025
Next Elicera Therapeutics earnings date
Q3 202514 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The company focuses on developing next-generation cell and gene therapies aimed at treating cancer through immune-based approaches. Elicera's pipeline includes four main drug candidates, two of which are in the field of oncolytic viruses and two in CAR T-cell therapies. Their proprietary iTANK (ImmunoTherapies Activated with Nap for efficient Killing) platform is designed to enhance the efficacy of these therapies. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq Stockholm.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage